Expressão das metaloproteinases de matriz 2 e 9 em cães com linfoma: associação com fatores prognósticos

Pós-graduação em Cirurgia Veterinária - FCAV

Alterações ultrassonográficas abdominais, hematológicas e de perfil bioquímico em cães com linfoma

Pós-graduação em Medicina Veterinária - FMVZ

Expressão de CD45+ na medula óssea e sangue periférico de cães com linfoma tratados com alta dose de ciclofosfamida suportada por transplante autólogo de medula óssea

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Classificação citológica e imunocitoquímica dos linfomas caninos

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Avaliação leucométrica e citofluorométrica do sangue periférico de cães com linfoma, após uso de rhG-CSF, submetidos à alta dose de ciclofosfamida seguida ou não de transplante autólogo de medula óssea

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Células T reguladoras em cães com linfoma multicêntrico: quantificação, em sangue periférico, no momento do diagnóstico e após a etapa inicial do tratamento quimioterápico

Pós-graduação em Medicina Veterinária - FCAV

Avaliação hematológica e imunofenotípica de cães com linfoma

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Tratamento do linfoma canino com poliquimioterapia seguida ou não de transplante autólogo de medula óssea

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Perfil de proteínas séricas em cães com linfoma multicêntrico de imunofenótipo B ou T: correlação com fatores prognósticos

Pós-graduação em Medicina Veterinária - FCAV

Resposta do linfoma cutâneo canino à lomustina: achados clínicos, imunohistoquímicos e expressão gênica

Pós-graduação em Medicina Veterinária - FMVZ

MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma

Purpose Mantle-cell lymphoma (MCL) has a variable natural history but is incurable with current therapies. MicroRNAs (miRs) are useful in prognostic assessment of cancer. We determined an miR signature defining aggressiveness in B-cell non-Hodgkin lymphomas (NHL) and assessed whether this signature aids in MCL prognosis.MethodsWe assessed miR expression in a training set of 43 NHL cases. The miR signature was validated in 44 additional cases and examined on a training set of 119 MCL cases from four institutions in Canada. miRs significantly associated with overall survival were examined in an independent cohort of 114 MCL cases to determine association with patient outcome. miR expression was combined with current clinical prognostic factors to develop an enhanced prognostic model in patients with MCL.ResultsFourteen miRs were differentially expressed between aggressive and indolent NHL; 11 of 14 were validated in an independent set of NHL (excluding MCL). miR-127-3p and miR-615-3p were significantly associated with overall survival in the MCL training set. Their expression was validated in an independent MCL patient set. In comparison with Ki-67, expression of these miRs was more significantly associated with overall survival among patients with MCL. miR-127-3p was combined with Ki-67 to create a new prognostic model for MCL. A similar model was created with miR-615-3p and Mantle Cell Lymphoma International Prognostic Index scores.ConclusionEleven miRs are differentially expressed between aggressive and indolent NHL. Two novel miRs were associated with overall survival in MCL and were combined with clinical prognostic models to generate novel prognostic data for patients with MCL. (C) 2013 by American Society of Clinical Oncology

Linfoma cardíaco primário em cão

Lymphomas are malignant neoplasm characterized by proliferation of lymphocytes that originate primarily in lymphoid organ such as lymph nodes, liver, spleen and bone marrow. However the feature of continuous migration of lymphocytes in different organs, this tumor can develop in any organ. Although lymphoma is a very common hematopoietic neoplasm in dogs, cardiac location is rare. The diagnosis of primary cardiac lymphoma may be performed when there is involvement of the heart and/or the pericardium without evidence of involvement in other organs. In veterinary medicine there are few reports on the diagnosis, treatment and prognosis of cardiac lymphoma. Therefore, the purpose of this report is to describe a case of cardiac lymphoma in which the patient responded favorably to chemotherapy employee with disease-free interval of 19 months and highlight the importance of including this neoplasm in the differential diagnosis of diseases that affect the cardiovascular system.

Transplante de medula óssea para suporte de células tronco hematopoiéticas em cães acometidos por linfoma

Lymphoma represents the most prevalent hematopoietic malignancy in small animal medicine. It is highly responsible to chemotherapy and therefore several protocols are used as therapeutic tools. For that reason, the bone marrow transplantation, enshrined in human medicine through initial trial in canine patients, has increasingly become the focus of studies in order to make it a reality also in veterinary medicine. First, the treatment with the chosen chemotherapy protocol is made. As complete remission of lymphoma is observed, it must be initiated the bone marrow harvesting. The obtained material is subjected to the processes of erythrocyte depletion, plasma depletion, cryoprotectants addition, total nuclear cells counting, hematopoietic progenitor quantification, analysis of cell viability and freezing. Following that, with radiotherapy or application of cyclophosphamide, the conditioning phase of the patient who is receiving the transplantation is carried out. The bags containing hematopoietic stem cells are then thawed and transplanted into the receptor organism. Support with hematopoietic stem cells allows the use of lethal doses of chemotherapy or radiotherapy and has been shown to considerably raise the disease remission time and survival rate of the canine patients

Importância do exame laboratorial no diagnóstico de linfoma em cães e gatos

Lymphoma is a cancer originating in solid hematopoietic tissue and is one of the most common tumors in dogs and cats. Usually the diagnosis is made late, when the disease is at an advanced stage, reducing the success of treatment, affecting the prognosis. Therefore, early diagnosis is the best tool to combat this increasingly common disease in veterinary medicine. Due to the diversity of presentations and forms of the disease, clinical signs are nonspecific and varied making the use of laboratory testing essential to lymphoma diagnosis in order of establishing the most appropriate treatment as quickly as possible, giving the patient a longer survival rate

Efeitos genéticos tardios de terapias para linfomas

O tratamento dos Linfomas de Hodgkin e Não - Hodgkin é baseado, atualmente, na combinação de drogas antineoplásicas, associadas ou não à radioterapia. Embora as taxas de cura sejam elevadas, sabe-se que tais terapias podem induzir mutações gênicas e cromossômicas que, mais tarde, podem ser responsáveis pela iniciação de novos processos carcinogênicos ou de doenças degenerativas relacionadas a danos genéticos. Sendo assim, o presente estudo teve por objetivo avaliar o efeito toxicogenético tardio (sobre os níveis de danos no DNA) das terapias antineoplásicas para linfomas. Para isso, foram incluídos no estudo 10 pacientes recém diagnosticados com linfoma (Grupo 1- Pré-terapia), 10 pacientes com história de linfoma e que finalizaram o tratamento antineoplásico há no mínimo dois anos (Grupo 2- Pós-terapia) e 10 indivíduos saudáveis (Grupo 3- Controles). Os linfócitos de sangue periférico foram utilizados para se avaliar os níveis de danos no DNA pelo teste do cometa. Além disso, foi avaliada a eficiência do sistema de reparo do DNA frente às lesões induzidas in vitro pelo peróxido de hidrogênio (H2O2). Os dados mostraram que não houve diferença estatisticamente significativa nos níveis de danos no DNA entre os três grupos. No entanto, foram observadas diferenças estatisticamente significativas no reparo das lesões induzidas pelo (H2O2), com o grupo controle apresentado maior indução de danos em comparação com aos demais grupos (p <0,05). Concluindo, os resultados não evidenciaram efeitos toxicogenéticos tardios decorrentes da exposição às terapias antineoplásicas para linfomas